Novo investors seek clarity on Wegovy weight-loss drug shortages

When Novo Nordisk publishes third-quarter results next week investors and analysts are hoping the company will clarify when limits on the supply of starter doses of its weight-loss drug Wegovy in the United States will cease. Novo's share price has nearly tripled since Wegovy was launched in June 2021 in the United States, where it has proved a phenomenal success, making the Danish drugmaker Europe's most valuable listed company, ahead of luxury group LVMH, worth about $437 billion. But Novo has struggled to keep up with soaring demand for the appetite-suppressing, anti-obesity drug, forcing it to limit the number of patients who can start treatment.